The U.S. Food and Drug Administration has announced safety reviews of the FDA-approved medications Regranex Gel, Ziagen and Videx.
The FDA said study data suggests there might be an increased risk of death from cancer in diabetic patients using Regranex (becaplermin) Gel to treat leg and foot ulcers.
The FDA said it was also studying data that indicate a higher risk of heart attack in patients infected with the human immunodeficiency virus who take Ziagen (abacavir) or Videx (didanosine) as part of their drug therapy.
Until all three reviews are completed, the FDA said health care professionals should evaluate the potential risks and benefits of each drug with their patients.
Copyright 2008 by United Press International
Explore further: Turbocharging drug development and production with less paperwork